Smith-Magenis sindrome and growth hormone deficiency by E. Spadoni et al.
ORIGINAL PAPER
Emanuela Spadoni Æ Patrizia Colapietro
Mauro Bozzola Æ Gian L. Marseglia Æ Luciana Repossi
Cesare Danesino Æ Lidia Larizza Æ Paola Maraschio
Smith-Magenis syndrome and growth hormone deficiency
Received: 16 October 2003 / Revised: 22 March 2004 / Accepted: 23 March 2004 / Published online: 8 May 2004
 Springer-Verlag 2004
Abstract Smith-Magenis syndrome (SMS) is a multiple
congenital anomaly/mental retardation syndrome
including physical and neurobehavioural features. The
disease is commonly associated with a ca. 3.7 Mb
interstitial deletion of chromosome 17p11.2, while a
1.1 Mb critical region has been identiﬁed, containing
about 20 genes expressed in multiple tissues. Haploin-
suﬃciency of one of them, RAI1, seems to be responsi-
ble for the neurobehavioural, craniofacial and
otolaryngological features of the syndrome, but not for
short stature, commonly seen in SMS patients with
chromosome deletion, implying the role of other genes
in the 17p11.2 region. Growth failure is a ﬁnal result of
several diﬀerent mechanisms involving decreased growth
hormone (GH) production, reduced tissue response to
GH, or impaired activity of epistatic factors. To our
knowledge, the association of GH deﬁciency with SMS
has never been reported and rarely investigated, despite
the very short stature of SMS patients. We describe a
girl with a full SMS phenotype and a typical 3.7 Mb
deletion of 17p11.2 who also has GH deﬁciency. After
starting replacement therapy, growth has signiﬁcantly
improved, her stature being now above both the 10th
percentile and her genetic target. Conclusion: We sug-
gest that an investigation of both growth hormone
secretion and function is carried out in patients with
Smith-Magenis syndrome and 17p11.2 deletion.
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Introduction
Smith-Magenis syndrome (SMS, OMIM 182290) is a
multiple congenital anomaly and mental retardation syn-
drome including physical, neurodevelopmental, and
behavioural features [2,8]. The facial appearance is
characterised by a broad square-shaped face, brachy-
cephaly, prominent forehead and mid-face hypoplasia;
micrognathia is present in infancy changing to relative
prognathism with age. Eyes are deep-set with up-slanting
palpebral ﬁssures, the nose is short and full-tipped, the
mouthhasdown-turnedcornersandaﬂeshyevertedupper
lip with a ‘‘tented’’ appearance [1]. Gradual height and
weight deceleration of post-natal onset is observed and
short stature, small hands and feet and brachydactyly are
the norm. Scoliosis, hearing loss and other otorhinolar-
yngological problems, including vocal cord nodules and
polyps, and ophthalmological defects, especially strabis-
mus and progressive myopia, are common. Hypercho-
lesterolaemia, which may require medical treatment, is
found in about 70% of patients [21]. Mild ventriculomeg-
aly of the brain, and cardiac and renal abnormalities are
observed in 33% of patients and hypothyroidsm and
immunoglobulin deﬁciency in 20% to 25%. All patients
havesomelevelofcognitive impairment,mostlymoderate,
and expressive language is signiﬁcantly impaired [19].
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Infantile hypotonia with feeding diﬃculties is observed in
most children.Marked hypersomnolence is noted in early
infancy, shifting at about 2–4 years of age to the typical
SMSpattern of sleep disturbanceswhich include diﬃculty
in falling asleep and frequent and prolonged night-time
awakenings [20]. Other distinctive behavioural features of
SMS are attention deﬁciency, hyperactivity, frequent
outbursts, temper tantrums, aggression towards self and
others, and stereotypies [19].
SMS is associated with an interstitial deletion of
chromosome 17p11.2, the majority of patients having a
common ca. 3.7 Mb deletion, ﬂanked by large, highly
homologous, low copy repeats [16]. These repeats are
deﬁned as proximal and distal SMS-REPs (SMS-REPP
and SMS-REPD), while a third copy repeat, designed
middle SMS-REP (SMS-REPM), lies between them with
an inverted orientation. Homologous recombination
and unequal crossing-over between the SMS-REPP and
SMS-REPD represent the mechanism responsible for
the common deletion and the reciprocal duplication.
Some SMS patients have smaller or larger sized
deletions and molecular analysis of ten patients with a
diﬀerent deletion from the common one allowed the
delineation of a ca. 1.1 Mb SMS critical region
(SMSCR) [3]. The discovery of three individuals with
phenotypic features consistent with SMS, but without
any ﬂuorescence in situ hybridisation (FISH) detectable
17p11.2 deletion, led Slager et al. [17] to identify three
diﬀerent truncating mutations of the RAI1gene. In all
cases the mutation was de novo conﬁrming that
haploinsuﬃciency of RAI1is responsible at least for the
neurobehavioural and craniofacial features of the
syndrome.
Adequate function of the growth hormone (GH)
pathway is essential throughout childhood to maintain
normal growth and bone maturation. While most cases
of GH deﬁciency are idiopathic, a few single gene
disorders, as well as a variety of other genetic disorders
and syndromes, are associated with deﬁciency of GH or
with its impaired activity [5]. In this context GH deﬁ-
ciency can be caused by alteration in the GH gene [13],
in genes that aﬀect the response to GH [26] or in other
loci through epistatic eﬀects [25]. To our knowledge, the
association of GH deﬁciency with SMS has never been
reported and GH secretion and bone age have been
rarely investigated in these patients [10,18], despite their
very short stature.
Here we describe a girl with a full SMS clinical
phenotype and a typical 3.7 Mb deletion of chromosome
17p11.2 who also has GH deﬁciency and whose growth
velocity dramatically improved after starting GH
replacement therapy.
Case report
Our patient, a girl, was born in 1994 to non-consan-
guineous parents. Her father died at the age of 41 years
due to drowning; he had been diagnosed with brain
astrocytoma at the age of 36. The mother and a 4-year-
old sister are healthy.
During pregnancy, ultrasound examination demon-
strated a mild intrauterine growth retardation and at
birth (40 weeks of gestation) the girl’s weight was 2730 g
(3rd–10th percentile), length was 48 cm (25th percentile)
and head circumference was 32.5 cm (3rd–10th percen-
tile). Gradual height and weight deceleration had been
noted since the age of 1 year. First tooth eruption was at
12 months and the anterior fontanelle closed at 24
months of age. When the girl was 5 years old, height had
fallen to the 3rd percentile, growth velocity was
3.4 cm/year ()3 SD) and bone age was retarded (2.5
years). A partial GH secretion deﬁciency was demon-
strated (GH peak: 6.68 ng/ml after arginine adminis-
tration and 1.7 ng/ml after insulin tolerance test) and
replacement therapy was started (0.2 mg/kg per week in
six doses administered subcutaneously at bedtime).
Early neuromotor milestones were achieved almost at
the expected times (independent walking at 18 months),
while language development was signiﬁcantly retarded
(at the age of 3 years, DQ was 78.8 on the Griﬃths
Developmental Scale). The girl also had mild hypotonia,
swallowing diﬃculty and food textural aversion.
Behavioural disturbances had been present since early
infancy and escalated with age. They consisted of temper
tantrums and outbursts, attention deﬁcit, hyperactivity,
self-injurious and stereotypic behaviours (particularly
hand and nail biting and teeth grinding). Sleep distur-
bances improved greatly after starting therapy with
acebutolol and melatonin [6]. During the ﬁrst years of
life, she exhibited occasional absence-like episodes and
at the age of 7 years, during a bout of high temperature,
she had seizures. Since the ﬁrst months of life, she had
suﬀered from recurrent otitis media and respiratory
infections and has a selective IgA deﬁciency.
On our ﬁrst clinical examination at the age of 7 years
(Fig. 1b), height was 114 cm (10th percentile), weight
was 17 kg (3rd percentile) and head circumference was
48 cm (far below the 3rd percentile). The girl presented
with brachydactyly, an unusual gait on tiptoe, Brown
syndrome of the right eye, mild astigmatism, and hoarse
voice. She also had some dysmorphic features: mild
up-slanting of the palpebral ﬁssures, slight low-set and
marked protrusion of ears, full-tipped nose, ﬂeshy
everted upper lip with ‘‘tented’’ appearance and slight
micrognathia. On otolaryngological examination, mild
bilateral conductive hypoacusia and a left vocal cord
nodule were found. Brain MRI scan, echocardiography,
renal ultrasound examination, vertebral column radi-
ography and evaluation of thyroid function gave normal
results. Repeated analyses (the last one at the age of 8
years) of blood triglycerides, cholesterol, LDL and HDL
were always normal. After starting GH replacement
therapy, growth velocity was 9 cm/year (+3 SD) in the
ﬁrst year and 8 cm/year (+2.5 SD) and 6.7 cm/year
(+1.4 SD) during the 2nd and 3rd years respectively. At
the age of 8 years and 3 months, her height was slightly
above the 10th percentile (122.5 cm), and higher than
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her genetic target for height (156 cm) (Fig. 2), span was
120 cm, upper/lower segment ratio was 1.16, while head
circumference was around the 3rd percentile (50 cm).
Materials and methods
Routine and high resolution chromosome studies were
performed on phytohaemagglutinin-stimulated blood
cultures by standard techniques. FISH analysis was
carried out on chromosome preparations obtained
from the patient’s lymphoblastoid cell lines. BAC clones
of 17p11.2 were selected from NCBI and UCSC web
sites (http://www.ncbi.nlm.nih.gov/ and http://geno-
me.ucsc.edu/) and purchased from the Childrens Hos-
pital Oakland (BAC-PAC Resources), or provided free
by the YAC Screening Centre (Dibit HSR, Milan, Italy),
and Dr. M. Rocchi (http://biologia.uniba.it/eca/). The
commercial probe for the SMS critical region was
purchased from ONCOR (Gaithersburg). The probes
Fig. 1 a Patient at age 1 year
showing a characteristic broad
square-shaped face and
prominent forehead. b By 7
years, her general appearance
seems to have changed and the
girl only shows some SMS
facial dysmorphism such as a
full-tipped nose and a ‘‘tented’’
mouth appearance
Fig. 2 Growth curve of the
patient. The bar above the 97th
percentile indicates the duration
and dosage of GH replacement
therapy. Bone ages are
indicated with an ‘‘x’’ at the
end of a horizontal line from
the actual age. The ﬁrst
evaluation of bone age was at 5
years (growth between 4 and 5
years was nil). Genetic target
(GT) is at the 10th percentile
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were labelled by nick-translation with digoxigenin-11-
dUTP (Roche Mannheim, Germany). The analysis was
performed according to Lichter and Cremer [11] with
minor modiﬁcations.
Results
Chromosome analysis after high resolution banding,
performed when the girl was 7 years old, revealed a
heterozygous interstitial deletion of the short arm of
chromosome 17 (17p11.2) in all the analysed metaphases
(Fig. 3). The mother had a normal karyotype; the father
was unavailable for testing.
The involvement of the SMS region in the proband’s
deletion was conﬁrmed by FISH experiments with the
D17S258 SMS probe (Oncor) and a panel of contiguous
region-speciﬁc BACs that gave a signal on one chro-
mosome 17 only in all the analysed metaphases (data not
shown). The centromeric deletion breakpoint was map-
ped within the SMS-REPP by FISH with RP11 218E15
(centromeric to the SMS-REPP [12]) that showed the
presence of two signals (Fig. 4a), and RP11 121A13
(telomeric to SMS-REPP and mapping within the
Fig. 3 Cutout of the normal and the deleted (arrowed) chromo-
somes 17
Fig. 4 FISH characterisation of
17p11.2 deletion breakpoints.
a RP11 218E15, centromeric to
SMS-REPP, gives two
distinguishable hybridisation
signals. b RP11 121A13,
telomeric to SMS-REPP, gives
a signal of diminished intensity
( arrowed) indicating that the
centromeric deletion breakpoint
maps within SMS-REPP.
c RP11 92B11, mapping within
SMS-REPD, shows a signal of
diminished intensity (arrowed).
d RP11 209J20, telomeric to
SMS-REPD, gives signals on
both chromosomes allowing
location of the telomeric
breakpoint within SMS-REPD.
e The diagram shows the map
(not to scale) of chromosome
17p11.2 with the placement of
the FISH clones used to deﬁne
the deletion breakpoints. The
arrows represent the orientation
of the SMS-REPs
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LCR17pC [23]) that showed a diminished signal on the
deleted chromosome 17 in comparison to the normal
homologue (Fig. 4b). The telomeric deletion breakpoint
was located within the SMS-REPD by FISH with RP11
92B11 (mapping within the SMS-REPD [12]) which
gave a signal of diminished intensity on the deleted
chromosome 17 (Fig. 4c) and RP11 209J20 (telomeric to
the SMS-REPD [23]) which gave signals on both chro-
mosomes 17 (Fig. 4d). Our reﬁned FISH study allowed
us to establish that our patient had the common 3.7 Mb
deletion located between SMS-REPP and SMS-REPD
(Fig. 4e).
Discussion
The patient we describe here is an 8-year-old girl with a
3.7 Mb deletion of chromosome 17p11.2, as observed in
more than 90% of SMS patients. Her behavioural
phenotype completely overlapped that observed in the
syndrome. She had some facial dysmorphism strictly
resembling that observed in SMS [1], namely a full-
tipped nose and ‘‘tented’’ mouth, even if her general
appearance seemed to have changed over the years, now
lacking the characteristic broad square-shaped face,
brachycephaly and prominent forehead (Fig. 1a,b). She
lacked fasting lipid proﬁle abnormalities and skeletal
problems, both present in about 70% of SMS patients
[21]. Orthopaedic manifestations of SMS have recently
been revalued by Spilsbury and Mohanty in 22 patients
[22]. They found that all the subjects had short stature
with projected mean height of 143 cm when skeletally
mature. At birth, our patient had a length of 48 cm (25th
percentile), but since the age of 1 year gradual deceler-
ation of height had been noted and, by the age of 5
years, her height had fallen to the 3rd percentile. Bone
age was also delayed and an isolated partial GH secre-
tion deﬁciency was demonstrated before the diagnosis of
SMS was accomplished. After starting GH replacement
therapy, growth has signiﬁcantly improved and now the
girl’s height is above both the 10th percentile and her
genetic target (Fig. 2).
To our knowledge GH deﬁciency and delayed bone
age have never been reported in SMS, but they have
been very rarely investigated [10,18]. The necessity of a
good co-operation of patients and families and
prolonged times to complete GH secretion testing may
have led to the exclusion of this analysis from study
protocols of SMS patients. On the other hand, if the
diagnosis of SMS is made in early childhood, short
stature can be regarded as a feature of the syndrome and
thus not further investigated. Interestingly, one patient
with 17p11.2 duplication has been reported having GH
secretion deﬁciency [15].
It is probable that growth failure is a ﬁnal common
result of several diﬀerent mechanisms involving
decreased GH production, reduced tissue response to
GH, or impaired activity of regulatory factors. GH
deﬁciency has been demonstrated in chromosome dele-
tion syndromes and implied in the pathogenesis of the
associated short stature [7,14]. In a series of 33 subjects
with the 18q syndrome, Cody et al. [4] identiﬁed a region
of approximately 2 Mb that was deleted in every GH
insuﬃcient patient. They pointed to one gene included in
this region, the galanin receptor 1, as candidate gene for
the GH insuﬃciency phenotype, due to its hypothalamic
involvement in GH regulation. No such genes, known to
be important in growth, have been identiﬁed to date in
the 17p11.2 region. The SMSCR contains about 20
genes widely expressed in multiple tissues [3]; haploin-
suﬃciency of RAI1seems to be responsible for the
neurobehavioural, craniofacial and otolaryngological
features of the syndrome. However, the three SMS pa-
tients with RAI1mutations do not have short stature,
implying that haploinsuﬃciency of another or other
genes in the 17p11.2 region is responsible for this clinical
feature in SMS patients with a chromosome deletion.
Investigations of GH metabolism in children with
chromosome deletion syndromes, such as SMS, might
uncover novel mechanisms and new genes involved in
normal and altered GH secretion and regulation path-
ways. This may also enhance the understanding of these
disorders and suggest potential treatment approaches.
GH replacement therapy has proved beneﬁcial in our
patient, possibly reducing also her risk of hypercho-
lesterolaemia and hypertriglyceridaemia as observed in
adult GH deﬁcient patients [24]. Similarly, in Prader-
Willi syndrome, GH administration has been shown to
improve body composition, sleep quality and pulmonary
function [9]. Therefore we suggest that screening of GH
secretion and function is carried out in other patients
with SMS and a 17p11.2 deletion.
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